Children with autism often find social interactions awkward, leaving them isolated. Now in a study appearing in ACS’ Journal of Medicinal Chemistry, scientists report that they have discovered a first-of-its-kind compound that promotes social interaction among laboratory mice that display autistic traits. The finding could lead to the development of drugs capable of improving social behaviors in those who have autism.
Autism spectrum disorders (ASD) affect about one in every 59 children, according to the U.S. Centers for Disease Control and Prevention. Although symptoms vary, these disorders are often characterized by impaired social interactions, limited communication skills and repetitive behaviors. A few studies have shown that oxytocin, a hormone that acts like a neurotransmitter in the brain, can improve the ability of some ASD patients to interpret emotional cues and interact with others. However, oxytocin can’t be taken orally, is rapidly metabolized when given via injection and doesn’t readily cross the blood-brain barrier. Several research groups have tried to develop drug candidates that overcome these obstacles with little success. So Marcel Hibert and colleagues wanted to determine if other compounds that could mimic oxytocin—and also activate its receptor—might hold the key to helping ASD patients.
Some compounds that bind the oxytocin receptor also bind to another set of receptors for vasopressin, an antidiuretic hormone. The researchers found that these compounds share a common benzoyl benzazepine component. They tested variations of this structure, eventually finding one that appeared to have similar traits as oxytocin without its drawbacks. The team tested the compound in laboratory mice that were genetically altered so they behaved as if they had ASD. When given the compound, called LIT-001, the mice exhibited increased and more prolonged nose contacts than before—an indication that the mice were more social after treatment. The researchers concluded that this new compound could be an important step toward the development of drugs to relieve certain ASD symptoms.
Can one model the social deficits of autism and schizophrenia in animals?
Marie-Céline Frantz et al. LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism, Journal of Medicinal Chemistry (2018). DOI: 10.1021/acs.jmedchem.8b00697
- Study reveals insights into how the brain learns new locomotor patterns
- Depression Screening: MedlinePlus Lab Test Information
- Researchers discover a weakness in a rare cancer that could be exploited with drugs
- U.S.-based patient advocacy organizations received majority of pharma donations, finds study
- UCL and AIIMS collaborates to increase academic and student exchange
- Mechanism behind how diabetes causes muscle loss revealed
- Hepatocellular carcinoma diagnosis, prognosis and treatment may improve by identifying a protein
- The American Heart Association issues new reference toolkit for healthcare providers
- Studies explore physiological dangers that climate change will have on animal life
- Penn study reveals increase in health-related internet searches before ER visits
- Intensive therapy during early stages of MS leads to better long-term outcomes
- Prenatal Fluconazole Exposure Increases Neonatal Risks
- Mental Health Screening: MedlinePlus Lab Test Information
- Study suggests birth mechanics are part of the process that leads to autism
- Unhealthy diet linked to poor mental health
- Study gives a snapshot of crocodile evolution
- Research finds steep rise in self-poisonings among young people
- American Gastroenterological Association announces “AGA Future Leaders Program”
- Scientists uncover new mechanisms regulating neural stem cells
- Combinations of certain insecticides turn out to be lethal for honeybees